Something to smile about
The future life course of 24-year-old Russell Agland hangs on the result of the Aridol asthma test he is about to take. 
MORE PATIENT PROFILES AND VIDEOSWelcome to Pharmaxis
Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.
Founded on an Australian discovery, Pharmaxis' products are now available worldwide.
Company Highlights
Phase 3 CF trial actively recruiting
Pharmaxis is undertaking two Phase 3 trials with Bronchitol, its new experimental therapy for patients with cystic fibrosis.
Bronchitol for Australia
In September 2008 Pharmaxis submitted a marketing application in Australia for Bronchitol as a treatment for bronchiectasis.
FDA New Drug Application Submitted for Aridol
Pharmaxis has submitted an NDA with the U.S. FDA for Aridol, a bronchial challenge test. (Australian pack shot shown)
New factory
The new factory in Sydney, Australia is getting close to completion.
